Applications of N-Tert-Butoxycarbonyl-4-Cyanophenyl-D-Alanine in Industrial Manufacturing

As a trusted producer of N-Tert-Butoxycarbonyl-4-Cyanophenyl-D-Alanine, our technical team supports demanding downstream operations in regulated environments. Below, we detail proven application segments and associated technical integration pathways for this specialty raw material.

1. Peptide Active Pharmaceutical Ingredient (API) Synthesis

This protected amino acid enables chemoselective chain elongation during solid-phase peptide synthesis for active pharmaceutical compounds. Its sterically hindered Boc group safeguards the amine moiety against premature reaction until targeted deprotection, while the cyano substituent offers functional diversity in novel API frameworks. Downstream manufacturers utilize this material to meet stringent purity and batch traceability requirements defined by pharmaceutical regulatory bodies worldwide.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• USP General Chapter <1047> and EP 5.2 on peptide synthesis
• FDA 21 CFR Part 210 & 211 (current Good Manufacturing Practice for Drugs)
• Ph. Eur. monographs for peptide APIs

Typical usage ratio

• Ranges from 0.95~1.10 molar equivalents per coupling step, depending on resin substitution and peptide sequence; optimization based on yield and purity during process validation.

Downstream process integration

• Loaded onto solid-phase resins via Fmoc or Boc strategy following pre-activation with recommended condensation reagents (e.g. HBTU, DIC); deprotected under acidic conditions prior to elongation or side-chain modification.

Final product types

• Peptide-based pharmaceutical APIs for injectable, oral, or topical formulations
• Custom library peptides for drug discovery platforms

2. Peptide Diagnostic Reagent Production

Specialty peptide manufacturers use this material when assembling sequence-specific diagnostic reagents, especially where cyano-modified building blocks impart enhanced binding or detection specificity. Its robust N-protection profile helps achieve reproducible purity levels and batch reproducibility. End users in clinical diagnostics require conformance with in vitro reagent quality standards and tight supply chain control to maintain assay integrity.

Industry compliance standards

• ISO 13485:2016 for Medical Device and Diagnostic Reagent Quality Management Systems
• IVDR (EU 2017/746) for in vitro diagnostic medical devices
• CLSI guidelines for synthetic reagent traceability
• Relevant sections of 21 CFR Part 820 Quality Systems Regulation

Typical usage ratio

• Typically dosed at 1.00 molar equivalent per synthetic step; concentrations adjusted per peptide length and resin loading during parallel synthesis.

Downstream process integration

• Included in iterative peptide chain assembly using automated synthesizers; enabled by controlled Boc removal for subsequent amino acid coupling and on-resin cleavage for reagent elution.

Final product types

• Fluorescently labeled peptides for immunoassays
• Antigenic peptides for ELISA kit calibration
• Affinity capture reagents for proteomics

3. Structure-Activity Relationship (SAR) Library Synthesis

Our material serves as a key chiral building block for customized combinatorial chemistry programs aimed at small molecule drug discovery. Its cyano group and Boc protection allow medicinal chemistry teams to generate diverse analog libraries using convergent synthesis routes under high-throughput protocols while ensuring the chirality and structural integrity required for meaningful SAR screening data.

Industry compliance standards

• GLP (Good Laboratory Practice) for research material generation
• OECD Principles of GLP
• Company-specific internal compound library documentation standards

Typical usage ratio

• Loaded at 0.90–1.05 molar equivalent depending on individual synthetic route yield; frequently optimized relative to parallel substrate libraries and automated dosing systems.

Downstream process integration

• Added in the early steps of solution-phase or microwave-assisted synthesis workflows for SAR library assembly; subsequent deprotection and side-chain diversification performed according to high-throughput protocols.

Final product types

• SAR compound libraries for lead identification
• Reference standards for medicinal chemistry assays

4. Chiral Building Block for Custom Small Molecule Synthesis

Chemical and contract manufacturing organizations incorporate this product as a protected chiral intermediate for high-purity small molecule synthesis, particularly where the presence of the 4-cyanophenyl motif is functionally required. Its compatibility with a variety of coupling and deprotection methodologies provides flexibility in multi-step routes that must align with stringent ISO and GMP production systems, supporting downstream applications ranging from pilot-scale synthesis to commercial launch.

Industry compliance standards

• ISO 9001:2015 for Quality Management Systems
• Relevant customer-requested GMP guidelines (e.g. ICH Q7)
• In-house analytical release and impurity control protocols

Typical usage ratio

• Applied at 0.98–1.15 molar ratios in stepwise reactions based on reaction efficiency, desired yield, and downstream recovery rates; adjustments determined after laboratory kinetic studies.

Downstream process integration

• Introduced in initial chiral center formation steps or used in late-stage diversification depending on route complexity; deprotected under controlled acidic conditions prior to downstream modification or final compound isolation.

Final product types

• Chiral pharmaceutical intermediates
• Advanced intermediates for agrochemical synthesis
• Custom performance chemicals

5. Specialty Peptide Reference Standard Preparation

Regulated chemical analysts and standards suppliers rely on this compound during synthesis of peptide reference standards, which support QC and method validation in highly regulated industries. Accurate quantitation and purity traceability are critical, and careful Boc management supports reproducible deprotection sequencing needed for analytical lot documentation accepted by global health authorities.

Industry compliance standards

• ISO 17034:2016 for reference material producers
• Ph. Eur. general monographs for reference standards
• USP General Chapter <11> Reference Standards
• GLP and GMP guidelines for analytical standard preparation

Typical usage ratio

• Dosed at stoichiometric to slight molar excess (1.00–1.08 eq.) to secure full incorporation in reference lot synthesis; batch size optimization according to downstream reference inventory planning.

Downstream process integration

• Employed in the protected chain assembly step of reference peptide synthesis; subjected to careful one-step deprotection and final purification using preparative HPLC.

Final product types

• Pharmaceutical peptide reference standards
• Certified calibration substances for analytical labs